Clinical trials
MDD clinical trials
Below are recruiting mdd clinical trials, each written for real people, not researchers. We’re tracking 109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06966401RecruitingPhase 3
Long-term safety study of a new depression treatment
This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.
Huntsville, AlabamaAges 18 years+ - NCT07196501RecruitingPhase 3
Study of a new add-on treatment for depression maintenance
This trial tests a new medication (NBI-1065845) added to your current antidepressant to see if it helps maintain improvement in depression. It is for people whose depression hasn't fully responded to their current oral antidepressant.
Oceanside, CaliforniaAges 18 years+ - NCT07533773Recruiting
Brain Activity Changes After Depression Treatment
This study measures how brain activity in specific regions changes after you receive electroconvulsive therapy (ECT) or magnetic seizure therapy (MST) for severe depression. Researchers use a non-invasive headband to monitor blood flow in your brain before and after treatment to better understand how these therapies work.
Hefei, AnhuiAges 12–65 - NCT07161700Enrolling by invitationPhase 2
Long-term safety study of SPT-300 for major depression
This study is for people who finished the earlier BUOY-1 study of SPT-300 and want to continue treatment. It tests the long-term safety and tolerability of SPT-300 for major depressive disorder, with or without anxious distress.
Chino, CaliforniaAges 18–66 - NCT07065240RecruitingPhase 2
Study of SPT-300 for major depression with or without anxiety
This trial tests an experimental oral medication, SPT-300, for people with major depressive disorder, even if they also have mild anxiety. The goal is to see if it helps improve mood safely.
Chino, CaliforniaAges 18–65 - NCT06605105Enrolling by invitationPhase 3
Long-term extension trial of CYB003 for depression
This long-term study is for people who already completed an earlier trial of the experimental drug CYB003 for major depression and who stayed on their regular antidepressant. It looks at the safety and effects of taking CYB003 again over many months.
Phoenix, ArizonaAges 18–85 - NCT05437588Recruiting
Blood-based biomarkers for suicide risk in teens with depression
This study looks at tiny blood particles (exosomes) and specific microRNAs to see if they can signal suicide risk and predict treatment outcomes in adolescents. If you qualify, your blood may be used to help researchers find better ways to understand and track suicidality and depression treatment response.
Birmingham, AlabamaAges 10–24 - NCT05585047Recruiting
Looking for brain and blood markers in major depression
This study looks at treatment response markers (signs in the body) in people with major depressive disorder (MDD). It may help researchers understand who is more likely to benefit from antidepressant treatment.
Changsha, HunanAges 18–60 - NCT05745194Recruiting
Mediterranean diet study for depression with inflammation
This study tests whether a Mediterranean-style diet can improve depression symptoms in people who have depression and higher inflammation in their blood. It may help by targeting nutrition-related inflammation that can worsen mood for some people.
Loures, Lisbon DistrictAges 18–70 - NCT05757791RecruitingPhase 2
Testing an SGLT2 diabetes drug for depression
This Phase 2 trial tests whether an SGLT2 medicine (like empagliflozin) can reduce symptoms of major depression. It may help people with moderate-to-severe depression who are otherwise eligible for the study.
New York, New YorkAges 18–65 - NCT05922878RecruitingPhase 2
ALTO-300 study for moderate to severe depression
This trial tests ALTO-300 as an add-on treatment for people with moderate to severe major depressive disorder (MDD). It aims to see whether ALTO-300 helps improve depression symptoms when you’re already on a stable antidepressant.
Phoenix, ArizonaAges 18–70 - NCT06132178RecruitingPhase 2
Psilocybin and rTMS for hard-to-treat depression
This study tests whether a combination of psilocybin (a psychedelic substance) and transcranial magnetic stimulation (rTMS, a noninvasive brain stimulation) can help people with treatment-resistant depression. It involves daily visits to the research center for about 2 weeks.
Austin, TexasAges 22–65 - NCT06236880RecruitingPhase 2
Testing GM-2505 for Moderate to Severe Depression
This trial tests a new oral medication, GM-2505, for people with moderate to severe major depressive disorder (MDD). The goal is to see if it is safe and well-tolerated, either as a stand-alone treatment or alongside a stable SSRI/SNRI antidepressant.
ManchesterAges 18–65 - NCT06319378RecruitingPhase 2
Psilocybin for cancer-related depression
This trial tests whether a single dose of psilocybin, a psychedelic medication, can safely and effectively treat major depression in people with cancer. If you have cancer and have been feeling depressed for at least a month, you may qualify.
Gothenburg, GöteborgAges 20–80 - NCT07696871RecruitingPhase 1/Phase 2
Cannabidiol oil for treatment-resistant depression
This trial tests if cannabidiol (CBD) oil can help people with major depression that has not improved with standard antidepressants. You will take CBD oil or a placebo while continuing your current antidepressant treatment to see if it improves your symptoms.
Tubarão, Santa CatarinaAges 18–69 - NCT06746155Recruiting
Predictors of relapse in major depression
This study looks at adults with major depressive disorder who have responded to treatment, to find out what might predict a relapse. You will wear a wrist activity monitor and complete questionnaires.
Calgary, AlbertaAges 18–70 - NCT06385405Recruiting
Brain stimulation for depression using EEG guidance
This trial uses a brain scan technique (EEG) to guide a treatment called repetitive transcranial magnetic stimulation (rTMS) for people with major depressive disorder. It aims to see if personalizing the treatment based on brain activity can help improve depression symptoms.
Shanghai, Shanghai MunicipalityAges 16–65 - NCT06409325Recruiting
Magnetic Seizure vs. Electric Shock for Depression
This study compares two brain stimulation treatments—Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT)—to see which works better for severe depression. If you are on a stable antidepressant and haven't had recent brain stimulation, this trial may be an option for you.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06467474Recruiting
Group Education Program for Depression
This trial tests a group education program (psychoeducation) for people with moderate to severe major depression. It’s designed to help you learn skills to manage your depression alongside medication.
São PauloAges 18–59 - NCT07694076Recruiting
Real-time brain feedback for depression
This trial uses a powerful MRI scanner to give you real-time feedback on brain activity linked to depression. You will learn to regulate that activity, which may reduce symptoms.
OxfordAges 18–65 - NCT06488586Recruiting
Ketamine vs Esketamine for treatment-resistant depression
This trial compares two forms of ketamine—given by IV or as a nasal spray—in people with major depression that hasn't improved after trying at least two other antidepressants. The goal is to see which treatment works better.
Kingston, OntarioAges 18–75 - NCT06601140Recruiting
Testing a smartphone app for tracking depression symptoms
This study tests a smartphone-based emotional monitoring device (EMOCARE) to see if it can accurately measure your mood compared to a standard depression questionnaire. It may help researchers find a simpler way to track depression symptoms.
AgenAges 18 years+ - NCT06675851RecruitingPhase 4
Dopamine changes in the brains of depressed and healthy people
This study uses brain scans to look at dopamine — a chemical messenger related to reward and mood — in people with depression and healthy volunteers. Researchers want to understand how dopamine changes in depression, which may lead to better treatments.
ViennaAges 18–65 - NCT06698666RecruitingPhase 3
Can statins help treat depression?
This trial tests if adding a statin (a cholesterol-lowering medicine) to your current depression treatment improves symptoms. It is for adults aged 20 to 45 with mild to moderate depression who are not already taking a statin.
Cairo, Al AbbasiaAges 20–45
Hear when a new MDD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mdd?
- Yes. Clin2 currently lists 109 recruiting mdd studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mdd trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mdd trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.